探索基于甲福明的药物组合,以减轻与糖尿病相关的动脉样硬化疾病
1Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.
World journal of diabetes
|April 16, 2025
概括
与GLP-1RA或SGLT-2抑制剂等药物结合的甲福明在治疗2型糖尿病和预防动脉样硬化并发症方面表现有前途. 需要进一步的研究来证实其他组合的益处.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是一种全球性健康问题,具有严重的血管并发症.
- 高血糖会损害血管细胞,破坏脂质代谢,促进动脉样硬化.
- 有效的管理需要血糖控制和血管保护.
研究的目的:
- 审查2型糖尿病 (T2DM) 与动脉样硬化疾病的组合疗法.
- 为了突出提供与甲福明一起提供血管益处的药物.
- 讨论新型治疗组合的潜在协同效应.
主要方法:
- 临床研究和动物研究的文献综述关于甲胺组合疗法.
- 对调查T2DM患者血管结果的研究分析.
- 对诸如GLP-1受体激动剂,SGLT-2抑制剂,低脂剂,抗氧化剂和补充剂等药物的证据评估.
主要成果:
- 与GLP-1RA或SGLT-2抑制剂结合的甲福明在T2DM中提供了经过证明的血管益处.
- 与甲福明和低脂抑制剂的联合治疗有助于控制葡萄糖和脂质.
- 动物研究表明,抗氧化剂/抗炎疗法和胆固醇和氨酸等补充剂可能会增强甲福林的疗效.
结论:
- 与GLP-1RA和SGLT-2抑制剂等特定药物相结合的甲福明,推用于动脉样硬化T2DM.
- 需要进一步的临床试验来验证其他组合的血管益处,包括低脂剂和补充剂.
- 优化药物组合对于改善T2DM管理和降低动脉样硬化风险至关重要.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
124
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
124
01:23Dipeptidyl Peptidase 4 Inhibitors
134
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
134
01:15Diabetes: Management and Pharmacotherapy
213
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
213
01:06Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
01:17Oral Hypoglycemic Agents: Sulfonylureas
163
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
163